Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3276-3282

  Kim, Sun H ^a   Abbasi, Fahim ^a   Lamendola, Cindy ^a   Liu, Alice ^a   Ariel, Danit ^a   Schaaf, Patricia ^a   Grove, Kaylene ^a   Tomasso, Vanessa ^a   Ochoa, Hector ^a   Liu, Yeheng V ^b,c   Chen, Yii Der Ida ^b,c   Reaven, Gerald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIRAGLUTIDE; OCTREOTIDE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; YOUNG ADULT;

BODY WEIGHT; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PREDIABETIC STATE; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84891883623     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0354     Document Type: Article

References (27)

1. Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a communitybased medical practice. J Am Coll Cardiol 2006;48:293-297
2. Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. Adults. Diabetes Care 2010;33:2355-2359
3. Association AD; American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36 (Suppl. 1):S11-S66
4. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
5. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350
6. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544
7. Saito T, Watanabe M, Nishida J, et al.; Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med 2011;171: 1352-1360
8. Heshka S, Anderson JW, Atkinson RL, et al.Weight loss with self-help compared with a structured commercial program: a randomized trial. JAMA 2003;289: 1792-1798
9. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
10. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebocontrolled study. Lancet 2009;374:1606-1616
11. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33: 1173-1175
12. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide andmetformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:2670-2678
13. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981;30:387-392
14. Knowles JW, Assimes TL, Tsao PS, et al. Measurement of insulin-mediated glucose uptake: Direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. Metabolism 2013;62:548-553
15. U.S. Department of Health and Human Services PHS. NHANES III anthropometric procedures video. Washington, DC, U.S. Government Printing Office, 1996
16. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112: 2735-2752
17. McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr 2006;84:813-821
18. Orskov L, Holst JJ, Møller J, et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39:1227-1232
19. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.Metabolism 2001;50:795-800
20. Holst JJ, Toft-NielsenMB, OrskovC, Nauck M, Willms B.Onthe effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. AnnNY Acad Sci 1996;805:729-736
21. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF; Diabetes Prevention Program Research Group. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 2009;32: 1583-1588
22. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results fromthe Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251
23. MarreM, Shaw J, BrändleM, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
24. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
25. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-2243
26. Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011;89:72-78
27. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 2013;15:42-54